David A. Siegel Incyte Corp Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Incyte Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,342,400 shares of INCY stock, worth $81.4 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

1,342,400

Previous 1,769,100 24.12%

Holding current value

$81.4 Million

Previous $111 Million 31.15%

% of portfolio

0.18%

Previous 0.26%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $24.1 Million - $28.4 Million	-426,700 Reduced 24.12%	1,342,400 $76.5 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $4.32 Million - $5.31 Million	82,800 Added 4.91%	1,769,100 $111 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $23.5 Million - $26.8 Million	-406,600 Reduced 19.43%	1,686,300 $97.4 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $54.7 Million - $67.8 Million	897,900 Added 75.14%	2,092,900 $130 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $22.2 Million - $27.2 Million	316,800 Added 36.07%	1,195,000 $86.4 Million

Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $9.26 Million - $11.6 Million	137,900 Added 18.63%	878,200 $70.5 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $6.45 Million - $8.08 Million	-97,500 Reduced 11.64%	740,300 $49.3 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $25.7 Million - $32.2 Million	387,600 Added 86.1%	837,800 $63.6 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $29.3 Million - $35.4 Million	443,700 Added 6826.15%	450,200 $35.8 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $411,710 - $481,715	6,500 New	6,500 $477,000
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $2.54 Million - $3.11 Million	-37,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $29.8 Million - $32.6 Million	-372,863 Reduced 90.97%	37,000 $3.11 Million
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $24.7 Million - $32.7 Million	-325,207 Reduced 44.24%	409,863 $33.3 Million
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $17.5 Million - $21.2 Million	-216,700 Reduced 22.77%	735,070 $63.9 Million
Q3 2020 Nov 16, 2020	SELL	$85.07 - $109.69 $3.92 Million - $5.06 Million	-46,112 Reduced 4.62%	951,770 $85.4 Million
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $726,964 - $1.07 Million	9,800 Added 0.99%	997,882 $104 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $16.9 Million - $23 Million	-267,000 Reduced 21.27%	988,082 $72.4 Million
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $2.57 Million - $3.37 Million	35,200 Added 2.89%	1,255,082 $110 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $902,967 - $1.07 Million	-12,400 Reduced 1.01%	1,219,882 $90.6 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $11.4 Million - $13.7 Million	154,600 Added 14.35%	1,232,282 $105 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $1.88 Million - $2.61 Million	29,600 Added 2.82%	1,077,682 $92.7 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $13.8 Million - $16.5 Million	235,800 Added 29.03%	1,048,082 $66.6 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $7.17 Million - $8.62 Million	116,100 Added 16.68%	812,282 $56.1 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $12.8 Million - $17.6 Million	209,900 Added 43.16%	696,182 $46.6 Million
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $41.9 Million - $50.9 Million	-503,900 Reduced 50.89%	486,282 $40.5 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $8.83 Million - $11 Million	94,373 Added 10.53%	990,182 $93.8 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $97.8 Million - $124 Million	895,809	895,809 $105 Million

Others Institutions Holding INCY

# of Institutions

617

Shares Held

215M

Call Options Held

366K

Put Options Held

445K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $13.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account